PCAC July 23-24: What the vote means and what it doesn't

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on whether to recommend seven peptides for addition to the Section 503A Bulks List — the roster of bulk substances that state-licensed 503A compounding pharmacies may lawfully compound with a valid prescription. It is important to understand what that vote was and was not: PCAC is an advisory body, its recommendations are non-binding, and a vote sits at roughly step two of a roughly six-step federal rulemaking process. Even a unanimous "yes" does not make any compound legally compoundable on its own; that outcome would still require the FDA to complete notice-and-comment rulemaking, a process that realistically takes 12 to 18 months at minimum after a favorable vote.

The seven compounds on the docket

The July 2026 docket covers exactly seven peptides: BPC-157, TB-500 (thymosin beta-4 fragment), KPV, MOTS-c, Emideltide, Epitalon, Semax. All seven were Category 2 going into the vote, meaning they may not be compounded under Section 503A today; six were recommended for the list and emideltide was not. The committee voted only on whether to recommend moving them toward Category 1 — the roster of substances a compounding pharmacy may prepare with a valid prescription.

What a "yes" vote actually does

• A YES vote is a formal, non-binding recommendation from the advisory committee that the FDA add the peptide to the 503A Bulks List (moving it from Category 2 toward Category 1).
• It signals that a majority of the committee found the available chemistry, safety, effectiveness, and historical-use evidence sufficient to support inclusion.
• It does NOT make the compound legal to compound — nothing about a pharmacy's or vendor's legal status changes on the day of the vote.
• It does NOT bind the FDA. The agency can decline to adopt the recommendation, propose narrower conditions, or take no action.
• It does NOT skip rulemaking. The compound would still need to pass through a proposed rule, a public comment period, and a final rule before becoming compoundable.
• Realistic timeline to actual legal compounding availability remains 12 to 18 months minimum after a favorable vote, and there is no guarantee the process reaches a final rule.

What a "no" vote means

• A NO vote is an advisory recommendation against adding the peptide to the 503A Bulks List at this time.
• The compound remains Category 2 — meaning it may not be compounded under 503A because the available data are considered insufficient or raise significant safety concerns — and stays non-compoundable pending further review.
• As with a yes vote, a no vote is non-binding; the FDA is not required to follow it and retains discretion over next steps.
• A no vote is not necessarily permanent: a substance can be re-examined if new safety, effectiveness, or characterization data are submitted and the FDA elects to revisit it in a future review cycle.

The realistic timeline

Even in the most favorable case, a "yes" vote is only the beginning. The FDA would still need to publish a proposed rule, open a public comment period, respond to comments, and issue a final rule before any of these peptides could be legally compounded. That process realistically takes 12 to 18 months at minimum — and there is no guarantee it reaches a final rule at all.

What's next

A second PCAC batch of five additional compounds is expected in February 2027, evaluated on a separate track from the July 2026 docket. These are additional Category 2 peptides scheduled for a later review cycle, and they will move through the same multi-step process: FDA scientific evaluation, an advisory (non-binding) PCAC vote, and — only if the agency proceeds — a proposed rule, public comment, and final rule. Nothing about this second batch is compoundable in the interim, and its own realistic timeline to any potential legal compounding availability would likewise run at least 12 to 18 months beyond a favorable February 2027 vote.

Open the live FDA PCAC tracker →